154 related articles for article (PubMed ID: 36276075)
1. DNAAF5 promotes hepatocellular carcinoma malignant progression by recruiting USP39 to improve PFKL protein stability.
Liu Y; Wu Q; Sun T; Huang J; Han G; Han H
Front Oncol; 2022; 12():1032579. PubMed ID: 36276075
[TBL] [Abstract][Full Text] [Related]
2. A functional loop between YTH domain family protein YTHDF3 mediated m
Zhou R; Ni W; Qin C; Zhou Y; Li Y; Huo J; Bian L; Zhou A; Li J
J Exp Clin Cancer Res; 2022 Dec; 41(1):334. PubMed ID: 36471428
[TBL] [Abstract][Full Text] [Related]
3. A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma.
Feng Y; Zhang Y; Cai Y; Liu R; Lu M; Li T; Fu Y; Guo M; Huang H; Ou Y; Chen Y
Cell Death Dis; 2020 Feb; 11(2):89. PubMed ID: 32015333
[TBL] [Abstract][Full Text] [Related]
4. USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo.
Yuan X; Sun X; Shi X; Jiang C; Yu D; Zhang W; Guan W; Zhou J; Wu Y; Qiu Y; Ding Y
Oncol Rep; 2015 Aug; 34(2):823-32. PubMed ID: 26081192
[TBL] [Abstract][Full Text] [Related]
5.
Zheng J; Luo J; Zeng H; Guo L; Shao G
Biomed Pharmacother; 2019 Nov; 119():109402. PubMed ID: 31514072
[TBL] [Abstract][Full Text] [Related]
6. An NAD
Dong L; Yu L; Li H; Shi L; Luo Z; Zhao H; Liu Z; Yin G; Yan X; Lin Z
iScience; 2020 Aug; 23(8):101351. PubMed ID: 32711345
[TBL] [Abstract][Full Text] [Related]
7. USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A
Pan XW; Xu D; Chen WJ; Chen JX; Chen WJ; Ye JQ; Gan SS; Zhou W; Song X; Shi L; Cui XG
Cancer Cell Int; 2021 Sep; 21(1):486. PubMed ID: 34544400
[TBL] [Abstract][Full Text] [Related]
8. EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL.
Pan M; Luo M; Liu L; Chen Y; Cheng Z; Wang K; Huang L; Tang N; Qiu J; Huang A; Xia J
J Exp Clin Cancer Res; 2024 Jan; 43(1):35. PubMed ID: 38287371
[TBL] [Abstract][Full Text] [Related]
9. USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma.
Dong X; Liu Z; Zhang E; Zhang P; Wang Y; Hang J; Li Q
Cell Signal; 2021 Sep; 85():110068. PubMed ID: 34197957
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma.
Ni W; Bian S; Zhu M; Song Q; Zhang J; Xiao M; Zheng W
Front Oncol; 2021; 11():629327. PubMed ID: 33718205
[TBL] [Abstract][Full Text] [Related]
11. High Expression of Ubiquitin-Specific Protease 39 and Its Roles in Prognosis in Patients with Hepatocellular Carcinoma.
Liao Y; Li L; Liu H; Song Y
Evid Based Complement Alternat Med; 2021; 2021():6233175. PubMed ID: 34987596
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
13. USP39-mediated deubiquitination of Cyclin B1 promotes tumor cell proliferation and glioma progression.
Xiao Y; Chen X; Hu W; Ma W; Di Q; Tang H; Zhao X; Huang G; Chen W
Transl Oncol; 2023 Aug; 34():101713. PubMed ID: 37302347
[TBL] [Abstract][Full Text] [Related]
14. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
15. USP39 regulates the growth of SMMC-7721 cells via FoxM1.
Yuan X; Sun X; Shi X; Jiang C; Yu D; Zhang W; Ding Y
Exp Ther Med; 2017 Apr; 13(4):1506-1513. PubMed ID: 28413501
[TBL] [Abstract][Full Text] [Related]
16. USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1.
Zhang Z; Liu W; Bao X; Sun T; Wang J; Li M; Liu C
Am J Cancer Res; 2022; 12(8):3644-3661. PubMed ID: 36119839
[TBL] [Abstract][Full Text] [Related]
17. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
18. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
19. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis.
Dou C; Mo H; Chen T; Liu J; Zeng Y; Li S; Guo C; Zhang C
Pathol Res Pract; 2021 Mar; 219():153345. PubMed ID: 33517164
[TBL] [Abstract][Full Text] [Related]
20. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
